India needs to focus more resources on evaluating applications for biologic drugs, while the biosimilar system needs to be tweaked, says Archana Shanker of Anand and Anand.
An Indian company is working on two approaches to creating a vaccine for the Zika virus, while several trademark applications have been filed for the term. Lucy Rana of SS Rana reports.
Over the past few years there have been a number of IP developments in the pharma and biotech industries in Japan, including on patent term extension and product-by-process claims. Osamu Yamamoto of Yuasa and Hara provides a roundup.
It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.
The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report.
The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications.
Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains.
Intellectual property rights should be used to help valorise agricultural biodiversity and traditional knowledge for the benefit of the global population as well as small farming communities around the world, says Graham Dutfield of the University of Leeds.
Fewer IPR petitions are instituted against biotech and pharma patents, and there is a higher survival rate of instituted claims in final written decisions compared to all technical fields combined. Melissa Gibson and Ruben Munoz of Akin Gump analyse the statistics.